1.

論文
論文
1. Coexistence of transthyretin- and Aβ-type cerebral amyloid angiopathy in a patient with hereditary transthyretin V30M amyloidosis
Sakai, Kenji ; Asakawa, Miwako ; Takahashi, Ryoichi ; Ishida, Chiho ; Nakamura, Ritsuko ; Hamaguchi, Tsuyoshi ; Ono, Kenjiro ; Iwasa, Kazuo ; Yamada, Masahito ; 坂井, 健二 ; 中村, 律子 ; 濵口, 毅 ; 小野, 賢二郎 ; 岩佐, 和夫 ; 山田, 正仁
出版情報: Journal of the Neurological Sciences.  381  pp.144-146,  2017-10-15.  Elsevier B.V.
URL: http://hdl.handle.net/2297/00049681
概要: 金沢大学附属病院神経内科<br />Embargo Period 12 months
2.

論文
論文
2. Inclusion body myositis with granuloma formation in muscle tissue
Sakai, Kenji ; Ikeda, Yoshihisa ; Ishida, Chiho ; Matsumoto, Yasuko ; Ono, Kenjiro ; Iwasa, Kazuo ; Yamada, Masahito
出版情報: Neuromuscular Disorders.  25  pp.706-712,  2015-09-01.  Elsevier
URL: http://hdl.handle.net/2297/43019
概要: Inclusion body myositis is a form of inflammatory myopathy. We identified 4 cases of inclusion body myositis showing gra … nuloma formation in muscle tissue and aimed to assess the features of this atypical form of inclusion body myositis. We retrospectively reviewed consecutive patients who satisfied European Neuromuscular Centre IBM Research Diagnostic Criteria 2011. Then, we assessed clinical profiles and pathological findings in patients with inclusion body myositis with granuloma and compared these findings with those of typical inclusion body myositis without granuloma. We identified 15 patients with inclusion body myositis. Four patients showed granuloma formation in muscle tissue in addition to typical pathological features of inclusion body myositis. Granulomas comprised a mixture of inflammatory cells, such as macrophages, epithelioid histiocytic cells, and lymphocytes. One patient was found to have mediastinal granulomatous lymphadenopathy; however, the evidence in other patients was insufficient for a diagnosis of systemic sarcoidosis. There were no significant differences between groups with and without granuloma regarding clinical manifestations, laboratory findings, response to immunomodulating therapies, or myopathological profiles. We established a new form of inclusion body myositis showing granuloma formation in muscle tissue. Inclusion body myositis and granuloma formation could have identical pathomechanisms concerning dysregulation of autophagy. © 2015 Elsevier B.V.<br />in Press / Embargo Period 12 months 続きを見る
3.

論文
論文
3. Inclusion body myositis with granuloma formation in muscle tissue
Sakai, Kenji ; Ikeda, Yoshihisa ; Ishida, Chiho ; Matsumoto, Yasuko ; Ono, Kenjiro ; Iwasa, Kazuo ; Yamada, Masahito
出版情報: Neuromuscular Disorders.  25  pp.706-712,  2015-09-01.  Elsevier B.V.
URL: http://hdl.handle.net/2297/43403
概要: Inclusion body myositis is a form of inflammatory myopathy. We identified 4 cases of inclusion body myositis showing gra … nuloma formation in muscle tissue and aimed to assess the features of this atypical form of inclusion body myositis. We retrospectively reviewed consecutive patients who satisfied European Neuromuscular Centre IBM Research Diagnostic Criteria 2011. Then, we assessed clinical profiles and pathological findings in patients with inclusion body myositis with granuloma and compared these findings with those of typical inclusion body myositis without granuloma. We identified 15 patients with inclusion body myositis. Four patients showed granuloma formation in muscle tissue in addition to typical pathological features of inclusion body myositis. Granulomas comprised a mixture of inflammatory cells, such as macrophages, epithelioid histiocytic cells, and lymphocytes. One patient was found to have mediastinal granulomatous lymphadenopathy; however, the evidence in other patients was insufficient for a diagnosis of systemic sarcoidosis. There were no significant differences between groups with and without granuloma regarding clinical manifestations, laboratory findings, response to immunomodulating therapies, or myopathological profiles. We established a new form of inclusion body myositis showing granuloma formation in muscle tissue. Inclusion body myositis and granuloma formation could have identical pathomechanisms concerning dysregulation of autophagy. © 2015 Elsevier B.V.<br />Embargo Period (12 months) 続きを見る
4.

論文
論文
4. CSF tau protein is a useful marker for effective treatment of superficial siderosis of the central nervous system: Two case reports
Ikeda, Tokuhei ; Noto, Daisuke ; Noguchi-Shinohara, Moeko ; Ono, Kenjiro ; Takahashi, Kazuya ; Ishida, Chiho ; Yoshita, Mitsuhiro ; Kawaguchi, Masahito ; Kawahara, Norio ; Iwasa, Kazuo ; Tomita, Katsuro ; Yamada, Masahito
出版情報: Clinical Neurology and Neurosurgery.  112  pp.62-64,  2010-01-01.  Elsevier BV
URL: http://hdl.handle.net/2297/19435
概要: 金沢大学附属病院神経内科<br />We report two cases of superficial siderosis (SS) of the central nervous system (CNS), which is caused … by chronic haemorrhaging into the subarachnoid space with haemosiderin deposition in the superficial portion of the CNS. Patient 1 had fluid collection in the spinal canal, which was reported as the source of the chronic bleeding. Patient 2 was bleeding from thickened dura at the level of the sacral vertebrae. Both of the patients had xanthochromic cerebrospinal fluid. We surgically repaired the sources of bleeding. Subsequently the cerebrospinal fluid (CSF) cleared and their symptoms were not aggravated for about 1 year. We measured several CSF markers of SS before and after surgery. Total tau protein (CSF-t-tau), phosphorylated tau protein (CSF-p-tau), iron (CSF-iron) and ferritin (CSF-ferritin) in the CSF were highly elevated at diagnosis. After surgery, the levels of CSF-t-tau and CSF-p-tau were markedly reduced while CSF-iron and CSF-ferritin had not decreased. It is suggested that CSF-t-tau and CSF-p-tau reflected the neural damage in SS and were useful to evaluate the effectiveness of SS therapies. © 2009 Elsevier B.V. All rights reserved. 続きを見る